Patient selection criteria for pilot studies on amelioration of non-neovascular age-related macular degeneration

Journal of Ocular Pharmacology and Therapeutics

Volumn 26, Issue 4, 2010, Pages 367-371

  Azuma, Mitsuyoshi ^a,b   Chung, Kelly ^b   Fujii, Atsuko ^a   Shearer, Thomas R ^b  

^a Senju Pharmaceutical Corporation Limited   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; EYE EXAMINATION; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT SELECTION; PILOT STUDY; RATING SCALE; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; CHOROIDAL NEOVASCULARIZATION; DISEASE PROGRESSION; FEMALE; GEOGRAPHIC ATROPHY; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; OPTIC DISK DRUSEN; PATIENT SELECTION; PILOT PROJECTS; RETINAL PIGMENT EPITHELIUM; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 77955575026     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2010.0042     Document Type: Article

References (11)

1. Gehrs, K.M., Anderson, D.H., Johnson, L.V., and Hageman, G.S. Age-related macular degeneration-emerging pathogenetic and therapeutic concepts. Ann, Med. 38:50-71, 2006.
2. Bird, A.C., Bressler, N.M., Bressler, S.B., et al. An international classification and grading system for age-related ma-culopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv. Ophthalmol. 39:367-374, 1995 [Review].
3. Chong, E.W.-T., Wong, T.Y., Kreis, A.J., Simpson, J.A., and Guymer, R.H. Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis. BMJ 335:755, 2007.
4. Stokkermans, T.J. What's new in clinical trials for treatment of dry AMD. Fifth Annual Guide to Retinal Diseases. Suppl. to Review of Optometry, November 2008. Available at www.revoptom.com .
5. Tamada, Y., Walkup, R.D., Shearer, T.R., and Azuma, M. Contribution of calpain to cellular damage in human retinal pigment epithelial cells cultured with zinc chelator. Curr. Eye Res. 32:565-573, 2007.
6. Ma, H., Tochigi, A., Shearer, T.R., and Azuma, M. Calpain inhibitor SNJ-1945 attenuates events prior to angiogenesis in cultured human retinal endothelial cells. J. Ocul. Pharmacol. Ther. 25:409-414, 2009.
7. Kanan, Y., Moiseyev, G., Agarwal, N., Ma, J.X., and Al-Ubaidi, M.R. Light induces programmed cell death by activating multiple independent proteases in a cone photore-ceptor cell line. Invest. Ophthalmol. Vis. Sci. 48:40-51, 2007.
8. Azuma, M., and Shearer, T.R. The role of calcium-activated protease calpain in experimental retinal pathology. Surv. Ophthalmol. 53:150-163, 2008 [Review]. Erratum in: Surv. Ophthalmol. 53:308-310, 2008.
9. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8. Arch. Ophthalmol. 119:1417-1436, 2001.
10. Csaky, K.G., Richman, E.A., and Ferris, F.L., 3rd. Report from the NEI/FDA ophthalmic clinical trial design and endpoints symposium. Invest. Ophthalmol. Vis. Sci. 49:479489, 2008.
11. Magnusson, K.P., Duan, S., Sigurdsson, H., et al. CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD. PLoS Med. 3:e5, 2006.